Novo Nordisk and Eli Lilly File for South Korean Approval of Oral Obesity Drugs

What Happened

Novo Nordisk and Eli Lilly have both filed for regulatory approval of their oral obesity medicines in South Korea, per industry reports, setting the two rivals up for a launch race next year in one of Asia's fastest-growing weight-loss markets.

Novo's candidate is its higher-dose oral semaglutide tablet — the pill formulation of the medicine best known as the Wegovy injection. Lilly's is its small-molecule oral GLP-1, orforglipron, which the US FDA cleared for chronic weight management earlier in September. With applications now lodged with Korea's Ministry of Food and Drug Safety, both companies are positioned to reach Korean patients within roughly a year, assuming standard review timelines.

The filings mark the first time two oral GLP-1 obesity products will compete head-to-head in a major Asian market from launch — a sharp break from the staggered injectable rollouts that defined the category's first five years.

Who Is Affected

• Korean patients with obesity stand to gain needle-free options in a market where approved injectable GLP-1s arrived later than in the US and Europe.
• Novo Nordisk and Eli Lilly face a rare simultaneous launch, where pricing, reimbursement, and early adoption will decide market share.
• Gray-market importers in Korea lose the convenience argument that has sustained unapproved injectable sales while legitimate supply lagged behind demand.
• Compounding and research-chemical sellers across Asia face the same squeeze US operators experienced once approved tablets reached pharmacies.
• Regulators elsewhere in Asia will watch the Korean review as a template for their own oral GLP-1 decisions.

Timeline

• 2019 — Low-dose oral semaglutide is approved for type 2 diabetes, proving the incretin class can work in tablet form.
• 2021–2023 — Injectable semaglutide and tirzepatide make GLP-1s the dominant obesity therapy but keep the category injection-only for weight loss.
• 2025 — Both companies report late-stage success for oral candidates in weight management.
• September 2026 — The US FDA clears Lilly's oral GLP-1 pill, and Novo's oral obesity tablet also reaches the US market, per regulatory announcements.
• September 2026 — Both companies file in South Korea, pointing to a 2027 launch race.

What This Means for Researchers

The Korean filings confirm that oral delivery is now the commercial center of gravity for incretin drug development, and that oral GLP-1s are being treated as global products from day one rather than follow-on formats for mature markets. For labs studying peptide analogs, the arrival of small-molecule agonists raises the bar for anything that requires injection or cold-chain handling.

It also sharpens a familiar warning: counterfeiters move faster than approval processes. Every delay between US approval and Korean reimbursement creates a window in which unapproved copies of oral GLP-1s — capsules, pressed pills, and drops marketed as research products — will appear online. Capsules are the easiest dosage form to counterfeit and the hardest to verify by eye. No oral GLP-1 obesity product is legally available to Korean consumers yet; anything sold there today claiming otherwise is unapproved by definition.

How to Verify Your Peptides

Whether you work with semaglutide or any other compound, identity and purity claims deserve independent confirmation. Our guides to how peptide testing works and HPLC versus LC-MS analysis explain what a legitimate certificate of analysis must contain. For semaglutide specifically, see our semaglutide testing and purity guide.

Safe Alternatives

Clinically approved GLP-1 therapies remain the only consumer-safe route to these medicines, and well-characterized research compounds are documented in our peptide profiles. Our vendor directory lists suppliers that publish third-party testing records, so you can avoid the mislabeled and unapproved products that trail every major drug trend.

Sources

Industry reports and regulatory announcements, September 2026.